Key statistics
As of last trade, Transgene SA (TGNA:BER) traded at 1.14, 21.41% above the 52 week low of 0.939 set on Aug 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.14 |
---|---|
High | 1.14 |
Low | 1.14 |
Bid | -- |
Offer | -- |
Previous close | 1.06 |
Average volume | 0.00 |
---|---|
Shares outstanding | 132.29m |
Free float | 65.61m |
P/E (TTM) | -- |
Market cap | 156.37m EUR |
EPS (TTM) | -0.2267 EUR |
Data delayed at least 15 minutes, as of Oct 09 2024 07:08 BST.
More ▼
Announcements
- Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
- Transgene présentera un poster sur les données actualisées de TG4050 au SITC 2024
- Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
- 2024 Half-Year Financial Report
- Transgene prévoit d’importants résultats cliniques d’ici fin 2024 et confirme sa visibilité financière jusqu’au 4ème trimestre 2025
- Rapport Semestriel 2024
- Mise à disposition du Rapport Financier Semestriel au 30 juin 2024
- Availability of Transgene’s Half-Year Financial Report as of June 30, 2024
- Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
- Le virus oncolytique BT-001 de Transgene et BioInvent montre une activité antitumorale prometteuse dans l’étude en cours de Phase I/IIa dans les tumeurs solides résistantes
More ▼